WO2005079269A3 - Method of treating carcinomas - Google Patents

Method of treating carcinomas Download PDF

Info

Publication number
WO2005079269A3
WO2005079269A3 PCT/US2005/004235 US2005004235W WO2005079269A3 WO 2005079269 A3 WO2005079269 A3 WO 2005079269A3 US 2005004235 W US2005004235 W US 2005004235W WO 2005079269 A3 WO2005079269 A3 WO 2005079269A3
Authority
WO
WIPO (PCT)
Prior art keywords
breast
carcinomas
cancer cells
cervical
treating carcinomas
Prior art date
Application number
PCT/US2005/004235
Other languages
French (fr)
Other versions
WO2005079269A2 (en
Inventor
Shalom Z Hirschman
Sharon A Malia
Original Assignee
Advanced Viral Res Corp
Shalom Z Hirschman
Sharon A Malia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advanced Viral Res Corp, Shalom Z Hirschman, Sharon A Malia filed Critical Advanced Viral Res Corp
Publication of WO2005079269A2 publication Critical patent/WO2005079269A2/en
Publication of WO2005079269A3 publication Critical patent/WO2005079269A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/20—Milk; Whey; Colostrum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A61K38/385—Serum albumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

In accordance with this invention, it has been found that liquid compositions containing an active ingredient formed from a mixture of peptides and nucleotides are capable of effectively inhibiting the invasion and migration of cancer cells, specifically of breast and cervical cancer cells and are effective in treating breast and cervical carcinomas when administered to patients who are affected with or have been treated for carcinomas of the breast or cervix.
PCT/US2005/004235 2004-02-13 2005-02-11 Method of treating carcinomas WO2005079269A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54461004P 2004-02-13 2004-02-13
US60/544,610 2004-02-13

Publications (2)

Publication Number Publication Date
WO2005079269A2 WO2005079269A2 (en) 2005-09-01
WO2005079269A3 true WO2005079269A3 (en) 2005-10-06

Family

ID=34886056

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/004235 WO2005079269A2 (en) 2004-02-13 2005-02-11 Method of treating carcinomas

Country Status (1)

Country Link
WO (1) WO2005079269A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6528098B2 (en) 1996-10-22 2003-03-04 Advanced Viral Research Corp. Preparation of a therapeutic composition

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5902786A (en) * 1997-04-15 1999-05-11 Advanced Viral Research Corp. Treatment of basal cell carcinoma with product R, a peptide-nucleic acid preparation
US20010006682A1 (en) * 1997-04-15 2001-07-05 Shalom Z. Hirschman Method for treating patients with suppressed immune systems
US6528098B2 (en) * 1996-10-22 2003-03-04 Advanced Viral Research Corp. Preparation of a therapeutic composition
US20030206962A1 (en) * 1997-04-15 2003-11-06 Hirschman Shalom Z. Method for treating cancer patients undergoing chemotherapy
US20040033244A1 (en) * 2002-05-28 2004-02-19 Advanced Viral Research, Corp. Treatment of cancers of lymphocytic cells with product R

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6528098B2 (en) * 1996-10-22 2003-03-04 Advanced Viral Research Corp. Preparation of a therapeutic composition
US5902786A (en) * 1997-04-15 1999-05-11 Advanced Viral Research Corp. Treatment of basal cell carcinoma with product R, a peptide-nucleic acid preparation
US20010006682A1 (en) * 1997-04-15 2001-07-05 Shalom Z. Hirschman Method for treating patients with suppressed immune systems
US20030206962A1 (en) * 1997-04-15 2003-11-06 Hirschman Shalom Z. Method for treating cancer patients undergoing chemotherapy
US20040033244A1 (en) * 2002-05-28 2004-02-19 Advanced Viral Research, Corp. Treatment of cancers of lymphocytic cells with product R

Also Published As

Publication number Publication date
WO2005079269A2 (en) 2005-09-01

Similar Documents

Publication Publication Date Title
WO2008045228A3 (en) Medical devices having porous regions for controlled therapeutic agent exposure or delivery
IL173348A (en) Thienopyridine compounds, pharmaceutical compositions comprising same and use thereof in the preparation of medicaments
WO2006058539A3 (en) Growth hormone secretagogue receptor 1a ligands
WO2003070283A3 (en) Agent for inhibiting development or progress of proliferative diseases and especially cancer diseases and pharmaceutical composition containing said agent
WO2005107726A3 (en) Method for the treatment of back pain
TW200604192A (en) Compounds and methods for inhibiting mitotic progression
EP2116245A3 (en) EGFR kinase inhibitor combinations for treating respiratory and gastrointestinal disorders
GEP20094845B (en) Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors
WO2005084295A3 (en) Fused heterotricyclic compounds as inhibitors of 17b-hydroxysteroid dehydrogenase 3
MY143795A (en) Tetrahydropyridoindole derivatives
JO2373B1 (en) W-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinease Inhibitors
WO2004006858A3 (en) Compounds, compositions, and methods employing same
WO2006024018A3 (en) Compositions for treating nociceptive pain
UA84954C2 (en) Fused pyrimidones usefuel in the treatment and the prevention of cancer
DE602005021970D1 (en) USE OF PEPTIDE COMPOUNDS FOR THE TREATMENT OF PAIN BY BONE CANCER, CHEMOTHERAPY AND NUCLEOSIDE-RELATED PAIN
WO2006001956A3 (en) Compositions for inhibiting cell growth and inducing apoptosis in cancer cells and methods of use thereof
WO2006060680A3 (en) Mda-7 protein variants having antiproliferative activity
WO2004009610A3 (en) Use of nucleoside compounds for nonsense suppression and the treatment of genetic diseases
WO2006048452A3 (en) Peptides for use in treating of obesity
WO2004103297A3 (en) Combination therapy with glatiramer acetate and mitoxantrone for the treatment of multiple sclerosis
WO2005051307A3 (en) Epha2 agonistic monoclonal antibodies and methods of use thereof
PL1732926T3 (en) Mitotic kinesin inhibitors
WO2004073615A3 (en) Deazaflavin compounds and methods of use thereof
WO2008014603A3 (en) Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
WO2000061141A3 (en) Methods and compositions for enhancing delivery of therapeutic agents to tissues

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase